Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response

Measurable residual disease (MRD) testing after initial chemotherapy treatment can predict relapse and survival in acute myeloid leukemia (AML). However, it has not been established if repeat molecular or genetic testing during chemotherapy can offer information regarding the chemotherapy sensitivit...

Full description

Bibliographic Details
Main Authors: Hong Yuen Wong, Anthony D. Sung, Katherine E. Lindblad, Sheenu Sheela, Gregory W. Roloff, David Rizzieri, Meghali Goswami, Matthew P. Mulé, Nestor R. Ramos, Jingrong Tang, Julie Thompson, Christin B. DeStefano, Kristi Romero, Laura W. Dillon, Dong-Yun Kim, Catherine Lai, Christopher S. Hourigan
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia (AML)
MRD
remission
measurable residual disease (MRD)
WT1 = Wilms tumor 1
somatic mutations in cancer
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00669/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00669/full

Similar Items